Posts

To infinity and beyond! The sufficiency requirements for open-ended ranges (T 1977/22)

Inventive step of treating a subpopulation of patients in view of prior art reporting a positive phase 3 clinical trial (T 1437/21)

Unambiguous disclosure without patent profanity (T 2171/21)

The criteria for the novelty and inventive step of pharmaceutical selection inventions (T 1356/21)

Gold Standard test for novelty reigns supreme, even for subranges (T 1688/20)

Boards of Appeal back rejection of special criteria for the novelty of purity inventions, but the Guidelines remain out of step (T 0043/18)

Does the requirement for a "technical contribution" in a novel selection survive? (if selecting from convergent lists) (T 1621/16)

Do we need a referral to the Enlarged Board of Appeal on the novelty of selection inventions?

2019 updates to the EPO Guidelines for Examination - the highlights